{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"16.0","value":"14.6"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"13.7","value":"11.6"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"17.9","value":"10.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"OS:The length of time from the start of treatment until death by any cause.","dispersionType":"Full Range","groups":[{"description":"All participants treated at level 1: APR-246 50mg/kg lean body weight (LBW) + Azacitidine 75mg/m\\^2","id":"OG000","title":"Phase 1B Dose Level 1"},{"description":"All participants treated at dose level 2: APR-246 75mg/kg lean body weight (LBW) + Azacitidine 75mg/m\\^2","id":"OG001","title":"Phase 1B Dose Level 2"},{"description":"All participants treated at dose level 3/ Phase 2 MTD : APR-246 100 mg/kg lean body weight (LBW) + Azacitidine 75mg/m\\^2","id":"OG002","title":"Phase 1B: Dose Level 3 / Phase 2 MTD"}],"paramType":"MEDIAN","populationDescription":"All participants who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}